The biology of preeclampsia  by Kanasaki, Keizo & Kalluri, Raghu
The biology of preeclampsia
Keizo Kanasaki1 and Raghu Kalluri1,2,3
1Division of Matrix Biology, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston,
Massachusetts, USA; 2Harvard-MIT Division of Health Sciences and Technology, Boston, Massachusetts, USA and 3Department of
Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA
Preeclampsia is a systemic disease that results from placental
defects and occurs in about 5–8% of pregnancies worldwide.
Preeclampsia is a disease of many theories, wherein
investigators put forward their favorite mechanistic
ideas, each with a causal appeal for the pathogenesis
of preeclampsia. In reality, the patho-mechanism of
preeclampsia remains largely unknown. Preeclampsia, as
diagnosed in patients today, is likely a heterogeneous
collection of disease entities that share some common
features but also show important differences. Therefore,
one single mechanism may never be found to explain all
the variants of preeclampsia. Current research must focus
on evaluating such diverse mechanisms, as well as the
possible common effector pathways. Here, we provide
a discussion of several possible mechanisms and putative
theories proposed for preeclampsia, with particular
emphasis on the recent discovery of a new genetic
mouse model offering new opportunities to explore
experimental therapies.
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Preeclampsia is a devastating pregnancy-associated disorder
characterized by the onset of hypertension, proteinuria, and
edema. Despite intensive investigation, our current under-
standing of the pathophysiology is limited. Emergent delivery
of the baby alleviates the maternal symptoms of preeclamp-
sia, but may lead to increased morbidity for the baby
secondary to iatrogenic prematurity. It is estimated that
about 15% of preterm births are because of preeclampsia. In
screening for this disease, hypertension associated with
pregnancy is a useful clinical feature; however, it is not a
specific finding and is often confused with gestational hyper-
tension. Preeclampsia affects about 5–8% of all pregnant
women. Surprisingly, the incidence of preeclampsia has
increased in recent years1 and may be much higher in
developing countries.
Recent speculations on the pathogenesis of preeclampsia
are mainly focused on the maternal symptoms of preeclamp-
sia. However, such attempts have failed to consider an
important feature of this disease: except in special cases (such
as postpartum preeclampsia), preeclampsia is a pregnancy-
induced disease that originates in the ‘hypoxic placenta’.
HISTORY OF PREECLAMPSIA
Eclampsia has been recognized clinically since the time of
Hippocrates. Two thousand years ago, Celsus described
pregnancy-associated seizures that disappeared after delivery
of the baby. Because these symptoms emerged without any
warning signs, the condition was named ‘eclampsia’, the
Greek word for ‘lightning’. In the mid-nineteenth century,
Rayer and Lever2,3 described the association of proteinuria
with eclampsia. In 1884, Schedoff and Porockjakoff first
observed the link between hypertension and eclampsia. Based
on these early observations, physicians and scientists in the
twentieth century began to realize that proteinuria and
hypertension were strong predictive indicators for the
onset of eclampsia. This prequel of eclampsia was termed
preeclampsia.4
BASIC PATHOLOGY AND PHYSIOLOGY OF PREECLAMPSIA
Hypertension
Hypertension in preeclampsia can lead to serious complica-
tions in both maternal and neonatal health. However, the
etiology of hypertension in preeclampsia remains unclear. In
normal human pregnancy, there is increased cardiac output
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with expanded circulatory volume and a decrease in
peripheral vascular resistance (Figure 1).5,6 During normal
human gestation, blood pressure is slightly decreased (with
minimal changes in systolic pressure but with evident
decrease in diastolic blood pressure) because of the dilation
of maternal vessels (Figure 1).6 Such vessel dilation allows for
fluid expansion in the mother and helps protect against
placental hypoperfusion (Figure 1).7 However, in preeclamp-
tic pregnancy, plasma volume is significantly decreased
despite the presence of massive edema.5 As a result, there is
reduced systemic perfusion, which can potentially lead to
damage of both the maternal organs and those of the baby8
(Figure 1).
In preeclamptic women, plasma renin activity (PRA) is
lower when compared with that of normal pregnant women9
(Figure 1). Renin, a key enzyme in the renin–angiotensin
system, acts as a volume sensor, and lower PRA has been
associated with expansion of circulatory volume.10 Does PRA
suppression in preeclampsia simply suggest that preeclampsia
is associated with volume-dependent hypertension? The
answer is not clear at this point and more studies are
required. In preeclampsia, increased vascular sensitivity for
vasoactive substances, such as angiotensin II, is reported11
(Figure 1). In addition, an increasing number of studies
suggest that the presence of agonistic autoantibodies to
angiotensin receptor type I (AT(1)-AAs) in the sera of
women with preeclampsia12 (Figure 1). The injection of such
AT(1)-AAs from preeclamptic women into pregnant mice
induces the key features of preeclampsia, such as hyperten-
sion, proteinuria, glomerular endotheliosis, placental ab-
normalities and embryonic defects. Such symptoms in
AT(1)-AA-injected pregnant mice are attenuated with
losartan, an AT1 receptor antagonist, or when a neutralizing
peptide against AT(1)-AAs is administered. This evidence
shows that despite the suppression of PRA in preeclampsia,
activation of the angiotensin receptor might be key to
understanding the mechanism/s of hypertension in pre-
eclampsia. The underlying mechanisms that drive the
production of AT(1)-AAs in preeclampsia are still unknown.
In the 1980s, several reports demonstrated the efficacy of an
angiotensin-converting enzyme inhibitor (captopril) in pre-
eclamptic women, with significant improvement of hyperten-
sion.13,14 These findings suggest that preeclampsia-associated
hypertension may result from overactive angiotensin receptor
signaling, or a vasoactive substance-induced vasoconstriction
(Figure 1). Unfortunately, AT1 receptor antagonists and ACE
inhibitors cannot be used in the clinic to treat women with
preeclampsia because of their serious teratogenic effects.
Remodeling of spiral artery/acute atherosis in the placenta
During human placental development, cytotrophoblasts
differentiate into two different types of invasive tropho-
blasts: multinuclear syncytiotrophoblasts and extravillous
trophoblasts.15,16 Such differentiation has a pivotal role in the
establishment of uteroplacental circulation, which occurs at
around 12–13 weeks of gestation.17 Extravillous trophoblasts
subsequently invade into the uterine vasculature (endo-
vascular invasion) and make direct contact with maternal
blood.16 It is speculated that such vascular remodeling
through the invasion of trophoblasts including replacement
of the smooth muscle layer of spiral arteries by trophoblasts,
results in vessels that are resistant to vasoactive substances,
thereby making such vessels independent of the control of
maternal blood pressure regulation. Consequently, normal
placental circulation is characterized by dilated vessels with
low resistance.18 In preeclampsia, however, such trophoblast
invasion is shallow and the spiral arteries are not remodeled
appropriately.19 As a result, the placental circulation does not
carry sufficient blood supply to meet the embryonic demand
due to these high-resistance/non-dilated vessels.
Acute atherosis is another prominent vascular alteration
that is often observed in preeclampsia, and also in idiopathic
intrauterine growth retardation.19,20 Such vasculopathy of the
spiral arteries is defined by fibrinoid necrosis of the vessel
wall, accumulation of lipid-laden macrophages, and a
mononuclear perivascular infiltrate.21 Interestingly, similar
vascular lesions have been observed in the vessels of patients
with autoimmune diseases such as lupus vasculopathy,22 and
in renal, cardiac, and hepatic transplant–graft rejection.21
Immunofluorescence analysis reveals extensive vascular
deposition of non-specific IgM and complement in these
lesions.23 Acute atherosis may contribute to the impairment
of feto-placental circulation and efficient nutrient/gas
exchange.24 It is not clear whether such acute atherosis is
the consequence of incomplete remodeling of vessels due to
shallow invasion of trophoblasts.
Kidney alterations and proteinuria
Increased proteinuria during pregnancy is associated with
poor outcome in preeclampsia. The kidney defect in
Normal pregnancy Preeclampsia
Higher than preeclampsia
Low
High
Decreased
(–)
High
Lower than normal pregnancy
High
Low
Increased
(+)
Low
PRA
Vascular resistance
Plasma volume
Sensitivity to vasoactive
substance
Autoantibodies for
AT1 receptor
2-ME
Dilation of
vasculature
Blood Vascular
contraction
Blood
Figure 1 |Pathophysiology of hypertension in preeclampsia.
As compared with normal pregnancy, preeclampsia is associated
with constricted, high-resistance vessels, lower plasma volume,
high sensitivity to vasoactive substances, presence
of autoantibodies against angiotensin type I (AT1) receptor,
and low plasma level of 2-ME. PRA, plasma renin activity; 2-ME,
2-methoxyestradiol.
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preeclampsia is characterized by a distinct glomerular
lesion known as ‘glomerular endotheliosis’, defined by an
enlarged glomerular volume with swelling of endothelial
cells and occlusion of capillary lumens. Mesangial cells of
the glomeruli may also show swelling. Such changes in the
endothelium are unique to preeclamptic glomeruli and are
not found in the endothelium of other organs in preeclamp-
tic women. Despite the presence of proteinuria, glomerular
podocytes appear relatively normal. Furthermore, glomerular
endotheliosis is not observed in the glomeruli of patients
with other hypertensive disorders. Glomerular endotheliosis
may contribute to the increased proteinuria and decreased
glomerular filtration rate observed in preeclampsia.25,26
Recent reports have suggested that circulating angiogenic
factors in the blood of preeclamptic women are responsible
for the emergence of glomerular endotheliosis. Among such
molecules, increased levels of soluble vascular endothelial
growth factor (VEGF) type 1 receptor (also known as soluble
Fms-like tyrosine kinase 1, sFlt1) is believed to contribute to
the onset of glomerular endotheliosis. sFlt1 (B100 kDa), a
transcriptional variant of full-length Flt1, is a secreted protein
without the transmembrane/cytoplasmic domains and serves
as an endogenous inhibitor of angiogenesis. Interestingly,
injection of sFlt1 protein25 or adenoviral delivery of sFlt126
induces glomerular endotheliosis-like lesions in mice and
rats. Such lesions are also found in mice treated with VEGF-
neutralizing antibody (VEGF-Ab).25 In addition, mice
injected with VEGF-Ab and sFlt1 develop proteinuria and a
decrease in podocyte expression of nephrin.25 These findings
suggest that depletion of VEGF in the glomeruli may be
responsible for glomerular endotheliosis and disruption of
glomerular microvascular homeostasis.25 In this regard, a
recent report identified a human-specific splicing variant of
VEGF type 1 receptor (designated sFlt1-14) that is qualita-
tively different from the previously described soluble receptor
(sFlt1) and functions as a potent VEGF inhibitor.27 sFlt1-14
is generated in a cell type-specific manner, primarily in
nonendothelial cells such as vascular smooth muscle cells.
The expression of sFlt1-14 is elevated in the placenta of
women with preeclampsia, and is specifically induced in
abnormal clusters of degenerative syncytiotrophoblasts
known as syncytial knots. More studies are required to
understand the role of sFlt1-14 in preeclampsia. Nevertheless,
it is possible that the non-specific antibody detection
methods to assay sFlt1 may have detected this novel
human-specific isoform (sFlt1-14) along with sFlt1, in many
of the previously reported studies.26,28,29,30
PATHOGENESIS OF PREECLAMPSIA
Placental hypoxia
Decreased blood circulation in the uteroplacental unit
(possibly as a result of abnormal placentation) may partially
explain the pathogenesis of preeclampsia.31,32 In 1939, Page
showed that relative ischemia in the placenta was associated
with eclampsia.33 In fact, Lunell et al.31 described a 50%
decrease in uteroplacental circulation in preeclamptic
women. In support of this observation Ogden et al.
demonstrated in 1940 that a 50% reduction of uteroplacental
circulation in dogs (by clamping the descending aorta)
resulted in approximately 25mmHg increase in blood
pressure.34 Subsequently, several animal studies have vali-
dated the association between preeclampsia-like symptoms
and reduced placental perfusion.35 These studies indicate that
the reduction in placental circulation is likely a fundamental
factor in the onset of preeclampsia. It has been hypothesized
that abnormal implantation in the first trimester of
pregnancy36 and/or defects in vascular remodeling19 are
major factors contributing to the reduction of placental
circulation. However, the precise mechanisms leading to
placental hypoxia in preeclampsia still remain unclear.
Placental hypoxia in the onset of maternal syndrome of
preeclampsia
How does placental hypoxia cause the maternal symptoms of
preeclampsia? This important question is still an open
debate. One theory is that reduced placental perfusion results
in the production of numerous placenta-derived circulatory
agents, which cause the maternal symptoms of preeclampsia.
Among these factors, sFlt1 is speculated to be an
important candidate molecule associated with the pathogen-
esis of preeclampsia.37–40 The underlying theory of how sFlt1
is involved in the pathogenesis of preeclampsia stems from
research by the Finnish group, Vuorela et al.37, showing that
VEGF is bound to a circulating protein in the amniotic fluid
and maternal serum. In 2000, the same research group
reported that sFlt1 is significantly elevated in the amniotic
fluid of preeclamptic women.38 This seminal work by Vuorela
et al. was the first report implicating sFlt1 in preeclampsia.
Subsequently, Fisher and co-workers showed that
cytotrophoblasts from preeclamptic placentae show higher
levels of sFlt1 in vitro when compared with control cells from
normal placentae.40 In 2003, Sugimoto et al.25 showed that
the neutralization of VEGF with sFlt1 or anti-VEGF
antibodies in mice leads to proteinuria. Later in 2003,
Maynard et al.26 reported that the concentration of sFlt1 in
the maternal serum of preeclamptic women was increased
when compared with normal pregnant women, and that
adenoviral delivery of sFlt1 in rats caused endotheliosis
and hypertension in males, and both pregnant and non-
pregnant female rats.
It is speculated that excess sFlt1 neutralizes both free
VEGF and free placental growth factor (PlGF) in maternal
circulation, resulting in endothelial damage and the onset of
the clinical syndrome.25,26 Although the placenta is believed
to be responsible for the excess sFlt1 production in
preeclampsia, this has not been explicitly shown because of
the pan-specificity of the antibodies to Flt1 and sFlt1. Clinical
studies have shown that sFlt1 is elevated in the blood of
women with preeclampsia26,28 and that PlGF concentration is
suppressed in the urine of women with preeclampsia.26,41,42
Interestingly, preeclampsia does not develop in all women
with high sFlt1 or low PlGF levels, and furthermore, can
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occur in some women with low sFlt1 and high PlGF levels.28
Therefore, although the involvement of placenta-derived
sFlt1 in the pathogenesis of preeclampsia is still being
explored, the utility of sFlt1 and PlGF levels as diagnostic
biomarkers for predicting preeclampsia is independently
being evaluated. In the AT(1)-AA-induced preeclampsia-like
disease in mice, elevation of sFlt1 is also found and is
speculated to contribute to the renal glomerular endothelial
damage; however, a connection to hypertension was not
found.12 Therefore, additional in-depth mechanistic studies
are required to elucidate the contribution of sFlt1 and
PlGF to the pathogenesis of preeclampsia.
Soluble endoglin (sEndoglin), which is also increased in
maternal serum in preeclampsia, is another circulating factor
that causes a preeclampsia-like phenotype in rodents.29 It is
speculated that adenoviral expression of sEndoglin induces a
preeclampsia-like phenotype in rats through the inhibition of
angiogenesis and activation of endothelial nitric oxide
synthase. Such effects of adenoviral-delivered sEndoglin
can be enhanced by co-infection with sFlt1-expressing
adenovirus,29 suggesting that sEndoglin may augment the
effects of sFlt1. Although such investigations may shed light
on the pathogenesis of preeclampsia, it is important to
consider that using an adenovirus system to deliver factors
relies on its capacity to infect many organs throughout the
body, including the liver. Adenoviral delivery leads to
concentrations of sFlt1 and sEndoglin that are substantially
higher in these animal models when compared with
physiological levels observed in preeclampsia.28,30 These data
in rats were analyzed using an enzyme-linked immunosor-
bent assay system specific for mouse sFlt1 and human
sEndoglin in rats infected with adenovirus carrying cDNA for
mouse sFlt1 and human sEndoglin. There was no evaluation
of endogenous rat-specific sFlt1 or sEndoglin. In addition,
increased viral infections may cause liver dysfunction in a
non-specific manner and may contribute to the vascular
dysfunction. Furthermore, the duration and change in the
rate of exposure to these molecules may be different in a
physiological condition observed in human preeclampsia.
Therefore these models need further characterization
to determine their physiological relevance to human
preeclampsia.26,29
Role of hypoxia-inducible factors in preeclampsia
Hypoxia-inducible factors (HIFs) have a pivotal role in the
regulation of tissue oxygen tension and gene expression. In
particular, HIF-1a is the master regulator of oxygen home-
ostasis. The accumulation and increased activity of HIFs have
been shown in the placentae of preeclamptic women.43 HIFs
may have an important role in the onset of preeclampsia by
way of effecting an alteration in the expression of hypoxia
target genes, such as VEGF and sFlt1. In addition, Caniggia
et al.44 have shown that accumulation of HIF-1a induces
the elevation of the transforming growth factor (TGF)-b3,
and that the resultant expression of TGF-b3 suppresses
trans-differentiation of trophoblasts. Trophoblast invasion
is a critical step for the remodeling of spiral arteries,
which allows the placenta to supply enough blood for
efficient nutrient/gas exchanges with the fetus. Together,
these studies indicate that suppression of HIF-1a may
serve as a possible therapeutic strategy for the treatment
of preeclampsia.
Th1 immunity and natural killer cells in preeclampsia
The maternal immune response against the fetus and
placenta has also been suggested to have an important role
in the pathogenesis of preeclampsia. In the maternal decidua,
invading trophoblasts encounter maternal immune cells,
mainly natural killer (NK) cells. NK cells are normally cleared
by full term. However, in preeclampsia, NK cells remain
active in the maternal decidua.47 Such activation of NK cells
might be responsible for the Th1-predominant inflammatory
response profile observed in preeclampsia, with increased
interferon-g and tumor necrosis factor-a levels. Such NK
cell-derived Th1 cytokines may therefore have a role in
the pathogenesis of preeclampsia, perhaps by inhibiting
trophoblast invasion locally, and/or by the induction
of endothelial damage and inflammation systemically.45
However, these potential mechanisms require further
investigation.
Deficiency of catechol-O-methyltransferase/2-methoxy-
estradiol in preeclampsia
Catechol-O-methyltransferase (COMT), a well-studied
candidate gene in psychiatric disorders such as schizophrenia,
is a catabolic enzyme involved in the degradation of a
number of bioactive molecules such as catecholamines and
catecholestrogens. Estradiol is metabolized by cytochrome
p450 and the resultant 17-hydroxyestradiol (one of the
catecholestrogens) is a substrate for COMT, which converts
17-hydroxyestradiol into 2-methoxyestradiol (2-ME), as a
rate-limiting step in estrogen breakdown (Figure 2). 2-ME
inhibits HIF-1a by possibly destabilizing microtubules
in trophoblasts,46 and can act in some cases as an anti-
angiogenic molecule. 2-ME is currently being evaluated as
a new therapeutic agent in the treatment of cancer, and
clinical trials with oral administration of 2-ME are underway.
Interestingly, during pregnancy, the concentration of mater-
nal circulatory 2-ME immediately increases46 and peaks at
term (18–96.21 nM between 37 and 40 weeks of pregnancy).47
In severe preeclampsia, the plasma level of 2-ME is
suppressed.46
Suppression of placental COMT in preeclampsia was
first described in 1988;48 however, the significance of
this phenomenon was not examined until recently. It has
been reported that COMT deficiency in mice is associated
with placental hypoxia and preeclampsia-like symptoms.46
COMT-deficient mice (COMT/) display a preeclampsia-
like phenotype, including pregnancy-induced hypertension
with proteinuria and increased fetal wastage as a result
of the absence in 2-ME. Interestingly, administration of
exogenous 2-ME ameliorates hypertension, proteinuria,
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placental defects, fetal wastage, acute atherosis, and glomerular
and placental endothelial damage in pregnant COMT/
mice (Figure 2).
How does deficiency in COMT and 2-ME lead to the
preeclampsia-like phenotype in mice? This may be linked to
HIF-1a accumulation in the placenta of COMT/ mice.
When COMT is present, 2-ME acts to suppress HIF-1a
accumulation and sFlt1 induction. In the COMT/ mice,
however, HIF-1a accumulation is associated with an
increased inflammatory response and endothelial damage.
In this regard, COMT/ mice treated with 2-ME showed a
decrease in NK cell recruitment, interferon-g production,
and endothelial damage (Figure 2). In addition, 2-ME can
induce trophoblast invasion specifically under hypoxic
conditions by suppression of HIF-1a-mediated TGF-b3
upregulation (unpublished data), suggesting that 2-ME may
have an important role in maintaining placental homeostasis.
This result is consistent with the HIF-1a/TGF-b3 theory
proposed by Caniggia et al.44 Furthermore, 2-ME may
directly function as a vasodilator in pregnant women49,50
(Figure 1).
The question remains how COMTmight be suppressed in
human preeclampsia. The activity of the COMT enzyme
displays a tri-modal frequency distribution in human
populations because of the presence of a functional
polymorphism in the coding sequence.51 This polymorphism
(rs4680: G-A nucleotide substitution) results in a Val to Met
amino-acid substitution at amino-acid residue position
158.51 The human COMTMet158 variant has a lower stability
and shows a lower enzymatic activity at physiological
temperature.51 The allelic frequency of this polymorphism
is found to be about 25–30% of the human population.
This functional COMT polymorphism is associated with
fetal growth restriction and abnormalities.52 Furthermore,
Nackley et al.53 reported that the combination of multiple
single nucleotide polymorphisms (SNPs) in the COMT gene
results in a significant decrease in COMT mRNA stability.
These findings suggest that the emergence of preeclampsia
could be associated with genomic alterations in the COMT
gene. However, these theories have to be tested and many
diverse SNP analyses should be conducted in multiple
families in different population cohorts. In addition, COMT
deficiency may not explain all variants of the preeclampsia
phenotype in humans; thus, if one cohort of patients is found
not to show relevant COMT polymorphisms, it does not
mean that all patients will follow this trend. Preeclampsia
most likely emerges because of diverse patho-mechanisms and
COMTmay be relevant in only a select patient population. In
addition, COMT deficiency may not be due to SNPs alone,
but may also result from other transcriptional/translational
control mechanisms leading to decreased protein levels.
With regard to COMT suppression, drugs currently
used in the clinic for the treatment of preeclampsia should
be evaluated carefully. Hydralazine is a well-known vaso-
dilator and is a widely accepted drug for the treatment of
preeclampsia. However, hydralazine has also been shown to
inhibit placental COMT activity.54 Importantly, some reports
indicate that the administration of hydralazine is associated
with placental abruption,55 which is a complication of the last
half of pregnancy frequently associated with preeclampsia
and often resulting in severe maternal and fetal morbidity
and mortality. In light of the recent findings regarding
COMT/2-ME deficiency in preeclampsia, the COMT-sup-
pressing activity of hydralazine needs careful reassessment.
COMT suppression is also observed in placental explants
following a-methyldopa administration, another anti-
hypertensive drug that is used in preeclamptic women.54
Therefore, suppression of COMT/2-ME needs to be carefully
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Figure 2 | The putative role of COMT/2-methoxyestradiol
(2-ME) in pregnancy. In normal pregnancy, 2-ME may have a role
in regulating hypoxia-inducible factor (HIF)-1a in diverse ways. In
preeclampsia, low COMT/2-ME levels may induce accumulation of
HIF-1a, vascular defect, placental hypoxia, and inflammatory
responses in the placenta. Such a response may induce placental
defects and result in suppression of placental-derived estradiol
and further reduction in 2-ME levels. COMT, catechol-
O-methyltransferase; CYP450, cytochrome 450.
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evaluated for its connection with possible drug-exacerbated
preeclampsia.
PERSPECTIVE
Although decreased placental perfusion due to poor placen-
tation is likely a key factor in the onset of preeclampsia, it is
unlikely to be the only factor that leads to preeclampsia
(Figure 3). For example, perfusion defects can also lead to
fetal growth restriction even in the absence of preeclampsia.
Furthermore, only one-third of the babies born to pre-
eclamptic women show growth restriction even in the
presence of placental defects.56 Placental perfusion defects
(vide supra) are often the consequence of abnormal
implantation and shallow invasion of trophoblasts; however,
these findings are also found in the placentae of pregnant
women with intrauterine growth restriction and in preterm
babies of non-preeclamptic women.57 Preeclamptic placentae
are sometimes larger than in normal pregnancy, and large
babies in women with obesity and gestational diabetes have
been associated with increased risk of preeclampsia.58
Therefore, although decreased perfusion of the placenta is a
key feature of preeclampsia, it is probably not sufficient to
explain all of the symptoms associated with preeclampisa.
An interesting alternate possibility is the consideration
of the fetal/placental weight ratio (FP ratio) as an important
determinant for the onset of preeclampsia. Although FP ratio
is lower in fetal distress, it is significantly increased in
preeclampsia when compared with normal pregnancy.59
Experimental models suggested that an increased FP ratio
is associated with a decreased placental blood supply
and normal/increased demand of the embryo;60,61 conse-
quently, an imbalance emerges between embryonic demand
and placental blood supply. Therefore, the efficiency of
placental blood supply (not the volume) may be important in
the pathogenesis of preeclampsia. In this regard, pregnant
COMT/ mice show increased FP ratio associated with
placental hypoxia,46 similar to that observed in preeclamptic
women.
In conclusion, more work is required to obtain new
clinically useful biomarkers and to better understand the
patho-mechanisms of this disease; in this regard the
discovery of sFlt1-14 may provide novel insights into the
pathogenesis of preeclampsia. It should be emphasized that
care should be taken to not use biomarkers assessment in
preeclampsia patients and preliminary rodent studies to
derive absolute conclusions regarding the pathogenesis of this
human pregnancy disorder.
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